Fig. 1: ALYREF is upregulated in NPC tissues and its high expression is associated with a poor prognosis in NPC patients. | Cell Death & Disease

Fig. 1: ALYREF is upregulated in NPC tissues and its high expression is associated with a poor prognosis in NPC patients.

From: ALYREF promotes the metastasis of nasopharyngeal carcinoma by increasing the stability of NOTCH1 mRNA

Fig. 1

A The expression levels of the m5C-related genes in NPC and NPN tissues from the 3 GEO databases (GSE12452, GSE53819, and GSE61218). B The mRNA levels of NSUN2 and ALYREF in NPC (n = 22) and NPN tissues (n = 10). C The mRNA levels of ALYREF in Bmi1-immortalized primary nasopharyngeal epithelial cell lines (NPEC2-Bmi1 and NPEC5-Bmi1) and NPC cell lines. D Protein levels of ALYREF in Bmi1-immortalized primary nasopharyngeal epithelial cell lines (NPEC2-Bmi1 and NPEC5-Bmi1) and NPC cell lines. E Representative IHC staining results of ALYREF are shown on the left, and the IHC scores of ALYREF are shown on the right. The results are based on 22 normal nasopharyngeal tissues, 161 nonmetastatic NPC tissues, and 31 metastatic NPC tissues. Scale bars represent l00 µm. F Kaplan−Meier survival curves of DMFS and OS for 161 NPC patients classified according to the ALYREF expression levels in tumor biopsies. G Time-dependent receiver operating characteristic (ROC) analysis showing the clinical risk score (TNM stage), the ALYREF risk score, and the combined clinical and ALYREF risk scores in the NPC cohort. NPC, nasopharyngeal carcinoma; NPN, non-NPC tissues; DMFS, distant metastasis‑free survival; OS, overall survival. DM, distant metastases. *P < 0.05, **P < 0.01, and ***P < 0.001.

Back to article page